

Wolfram-Hubertus Zimmermann is Professor and Director of the Institute of Pharmacology and Toxicology at the University Medical Center Göttingen. His research interests include: (1) development and translation of stem cell-based tissue engineered therapeutics; (2) therapeutic genome editing; (3) human organoids for disease modelling and drug discovery; (4) inter-cellular and inter-organ cross-talk. Major organs/tissue of interest include heart muscle, skeletal muscle, nervous system, and connective tissue. As pioneer in human pluripotent stem cell research and its translation into practical use Zimmermann is the initiator of the first-in-human BioVAT-HF-DZHK20 trial, which is testing tissue engineered heart repair with Engineered Human Myocardium (EHM) from induced pluripotent stem cells in patients with advanced heart failure. Zimmermann is the speaker of the German Center for Cardiovascular Research (DZHK) partner-site Lower Saxony with a focus on patient-tailored heart failure therapies and coordinator of the Leducq Foundation transatlantic network of excellence on "Genome Editing the Failing Heart" as well as the IndiHeart and AutoOrgan Consortia on individualized tissue engineered heart repair and development of automated drug screens in engineered tissue to reduce the need for animal experimentation. His track record includes >200 publications, 17 patents, and the founding of several spin-offs (e.g., Repairon, myriamed, MyriaMeat).